查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1799105

全球製药和生物技术领域的人工智慧市场

Artificial Intelligence (AI) in Pharma and Biotech
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球製药和生物技术领域的人工智慧 (AI) 市场规模将达到 90 亿美元

2024年，全球製药和生物技术领域的人工智慧 (AI) 市场规模估计为31亿美元，预计2024年至2030年期间的复合年增长率将达到19.2%，到2030年将达到90亿美元。药物发现和开发应用是本报告分析的细分领域之一，预计其复合年增长率将达到17.9%，到分析期结束时规模将达到26亿美元。临床试验和优化应用细分领域在分析期间的复合年增长率预计将达到17.8%。

美国市场规模估计为 8.228 亿美元，中国市场预计复合年增长率为 18.3%

美国製药和生物技术领域的人工智慧 (AI) 市场规模预计在 2024 年达到 8.228 亿美元。作为世界第二大经济体，中国预计到 2030 年市场规模将达到 14 亿美元，在 2024-2030 年的分析期内，复合年增长率为 18.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为 17.5% 和 16.8%。在欧洲，预计德国市场的复合年增长率约为 14.3%。

全球製药和生物技术领域的人工智慧 (AI) 市场—主要趋势和驱动因素摘要

人工智慧将如何彻底改变药物发现和开发生命週期？

人工智慧正在透过加速和优化整个药物发现和开发过程，极大地重塑製药和生物技术产业。传统的药物开发是一项昂贵且耗时的工作，通常需要十多年的时间，耗资数十亿美元才能将新药推向市场。人工智慧正在改变这种模式，它能够快速分析大量资料集，包括基因组学、蛋白质组学和临床试验记录，以确定可行的药物标靶并预测化合物行为。机器学习演算法可以筛选数千种潜在分子，并根据预测的功效、毒性和生物利用度对它们进行排序，从而简化临床前筛检阶段。人工智慧生成模型甚至可以设计出满足特定治疗要求的新型分子结构。此外，人工智慧正在改进生物标记的选择和检验，帮助研究人员更有效地将药物与正确的患者群体配对。这些技术进步不仅加快了早期研发速度，也降低了昂贵的后期临床试验失败的风险。自然语言处理工具正被用来分析科学文献、专利和临床资料库，发掘先前被忽视的洞见。透过将真实世界证据与历史数据结合，人工智慧可以增强预测模型，支持假设生成，并在开发过程中做出更明智的「通过/不通过」决策。最终，我们建立了一个更敏捷、数据主导的药物发现模型，从而缩短上市时间并提高临床成功率。人工智慧在药物开发中的作用已不再局限于实验阶段。它正成为医药创新的重要工具，帮助企业更快、更有效率地为患者带来新的治疗方法。

人工智慧在临床试验、个人化医疗和法规遵循方面发挥什么作用？

人工智慧正在对临床试验管理、个人化医疗和监管工作流程产生深远的影响。这些领域传统上充满了复杂性、多变性和低效率。在临床试验中，人工智慧被用于优化患者招募，这是临床试验实施中最大的瓶颈之一。透过分析电子健康记录、基因数据和健康的社会决定因素，人工智慧系统可以更快地识别出合格的患者，并预测他们坚持治疗和产生反应的可能性。人工智慧还支援自适应试验设计，其中通讯协定根据输入资料即时修改，从而提高试验效率和统计能力。在个人化医疗中，人工智慧对于破解每个患者的生物学独特性并将其与标靶治疗相匹配至关重要。演算法分析基因组序列、蛋白质表达，甚至微生物组图谱，以预测药物反应并最大限度地减少副作用，为更个人化的治疗计划铺平道路。在监管业务中，人工智慧透过自动更新指南、发出安全警告和监控不同市场的标籤要求来帮助确保合规性。智慧型文件处理工具正被用于准备提交资料、识别差异并简化与FDA和EMA等监管机构的互动。药物安全检测是另一个受益于人工智慧的领域，机器学习系统被用于检测来自社群媒体、临床记录和上市后报告等不同资料来源的不利事件讯号。这些功能可以减少人工工作，并提高安全评估的准确性和及时性。透过改变临床、个人化和监管格局，人工智慧不仅加速了从实验室到患者的整个过程，还确保治疗更安全、更有效，并更好地满足个人需求。

製药和生技公司如何将人工智慧融入经营模式和研发基础设施？

为了在创新主导的环境中保持竞争力，製药和生物技术公司正越来越多地将人工智慧纳入其核心业务策略和研发基础设施。大型製药企业正在与人工智慧Start-Ups和高科技公司建立策略伙伴关係，共同开发用于靶点识别、化合物筛检和测试优化的平台。这些联盟提供了获取专业知识和独特数据集的途径，从而显着缩短了研发时间。许多公司也正在建立内部人工智慧卓越中心，聘请资料科学家、生物资讯学家和计算化学家，以整合各部门的人工智慧能力。云端基础平台和高效能运算正被用于处理基因组学、临床研究和数位健康应用产生的大量数据。主导的平台正被用于投资组合的优先排序，帮助决策者根据预测分析来评估哪些资产应该推进或搁置。在製造业，人工智慧支援流程优化、品管和预测性维护，确保产品品质始终如一併降低营运成本。在销售和行销方面，人工智慧工具可以分析市场趋势、处方模式和客户回馈，从而为医疗服务提供者和患者制定个人化的互动策略。此外，人工智慧正在数位治疗和伴随诊断领域不断拓展其作用，助力开发将传统药物与软体主导的监测和行为干预相结合的综合治疗解决方案。转向以人工智慧为中心的经营模式并非仅限于大型企业。新兴生物科技公司从一开始就利用人工智慧来实现差异化、建立精实营运并吸引投资。随着人工智慧的日趋成熟，它正成为製药价值链各个阶段的策略赋能者，培育创新、速度和精准的文化。

是什么推动了人工智慧在全球製药和生物技术市场的持续成长？

人工智慧在製药和生物技术市场的成长是由不断增长的医疗保健需求、不断扩大的数据集、技术创新以及良好的监管和投资环境共同推动的。包括癌症、阿兹海默症和罕见遗传疾病在内的慢性和复杂疾病的全球负担迫切需要更快、更有效的治疗方案。人工智慧可以透过加速药物发现和提高治疗精度来帮助满足这一需求。电子健康记录、基因组定序和穿戴式健康设备的广泛应用导致了大量结构化和非结构化资料的积累，为人工智慧模型提供了动力。自然语言处理、机器学习和神经网路的技术进步使得能够以以前难以想像的方式分析这些数据，从而获得指南药物开发、临床决策和打入市场策略的见解。旨在促进生命科学领域人工智慧创新的政府倡议和官民合作关係也透过为研究和部署提供资金和政策支援来支持成长。专注于人工智慧的生物科技公司的创业投资持续激增，反映出人们对人工智慧赋能药物开发的市场潜力充满信心。精准医疗的兴起和以患者为中心的医疗保健的推广，进一步推动了对能够实现个人化治疗策略的人工智慧工具的需求。全球製药公司也面临着降低成本和提高研发效率的压力，这使得人工智慧成为持续创新的一个有希望的解决方案。随着成功案例的增多，包括人工智慧发现的候选药物进入临床试验，生命科学领域对人工智慧的信任和采用持续成长。这些因素共同推动製药和生物技术领域人工智慧市场的强劲持续扩张，标誌着一个数据主导、技术赋能的医疗保健创新新时代的到来。

部分

应用程式（药物发现和开发应用程式、临床试验和优化应用程式、预测性维护和品管应用程式、药物发现目标识别应用程式、疾病诊断和预后应用程式和其他应用程式）、最终用户（製药和生物技术公司、学术和研究机构和其他最终用户）

受访公司范例

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP38499

Global Artificial Intelligence (AI) in Pharma and Biotech Market to Reach US$9.0 Billion by 2030

The global market for Artificial Intelligence (AI) in Pharma and Biotech estimated at US$3.1 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 19.2% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Clinical Trials & Optimization Application segment is estimated at 17.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.8 Million While China is Forecast to Grow at 18.3% CAGR

The Artificial Intelligence (AI) in Pharma and Biotech market in the U.S. is estimated at US$822.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Artificial Intelligence (AI) in Pharma and Biotech Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing the Drug Discovery and Development Lifecycle?

Artificial Intelligence is dramatically reshaping the pharmaceutical and biotechnology industries by accelerating and optimizing the entire drug discovery and development process. Traditional drug development is an expensive, time-consuming endeavor that often takes over a decade and costs billions of dollars to bring a single new drug to market. AI is changing this paradigm by enabling the rapid analysis of massive datasets, such as genomics, proteomics, and clinical trial records, to identify viable drug targets and predict the behavior of chemical compounds. Machine learning algorithms can sift through thousands of potential molecules and rank them based on predicted efficacy, toxicity, and bioavailability, thereby streamlining the preclinical screening phase. Generative AI models are even capable of designing novel molecular structures that meet specified therapeutic requirements. Moreover, AI is improving the selection and validation of biomarkers, helping researchers match drugs to the right patient populations more effectively. These innovations not only speed up early-stage R&D but also reduce the risk of failure in costly late-stage trials. Natural language processing tools are being used to analyze scientific literature, patents, and clinical databases to uncover previously overlooked insights. By integrating real-world evidence and historical data, AI enhances predictive modeling, supports hypothesis generation, and allows for more informed go/no-go decisions during development. The net result is a more agile and data-driven drug discovery model, reducing time to market and improving the chances of clinical success. AI’s role in drug development is no longer experimental; it is becoming an essential tool for pharmaceutical innovation, helping companies bring new treatments to patients faster and more efficiently.

What Role Is AI Playing in Clinical Trials, Personalized Medicine, and Regulatory Compliance?

AI is making a profound impact on clinical trial management, personalized medicine, and regulatory workflows, areas that are traditionally laden with complexity, variability, and inefficiency. In clinical trials, AI is being deployed to optimize patient recruitment, one of the biggest bottlenecks in trial execution. By analyzing electronic health records, genetic data, and social determinants of health, AI systems can identify eligible patients faster and predict their likelihood of adherence and response to treatment. AI also supports adaptive trial designs, where protocols are modified in real-time based on incoming data, improving trial efficiency and statistical power. For personalized medicine, AI is crucial in deciphering the biological uniqueness of individual patients and matching them with targeted therapies. Algorithms analyze genomic sequences, protein expressions, and even microbiome profiles to predict drug response and minimize adverse effects, paving the way for more customized treatment plans. In regulatory affairs, AI helps ensure compliance by automating the monitoring of guideline updates, safety alerts, and labeling requirements across different markets. Intelligent document processing tools are being used to prepare submissions, identify inconsistencies, and streamline interactions with regulatory agencies such as the FDA and EMA. Pharmacovigilance is another area benefiting from AI, where machine learning systems are used to detect adverse event signals from disparate data sources, including social media, clinical notes, and post-marketing reports. These capabilities reduce manual workload and enhance the accuracy and timeliness of safety assessments. By transforming the clinical, personalized, and regulatory landscape, AI is not only accelerating the path from lab to patient but also ensuring that treatments are safer, more effective, and more tailored to individual needs.

How Are Pharma and Biotech Companies Integrating AI into Their Business Models and R&D Infrastructure?

Pharma and biotech companies are increasingly embedding AI into their core business strategies and R&D infrastructure to stay competitive in an innovation-driven landscape. Large pharmaceutical firms are forming strategic partnerships with AI startups and tech companies to co-develop platforms for target identification, compound screening, and trial optimization. These collaborations enable access to specialized expertise and proprietary datasets that can significantly accelerate R&D timelines. Many companies are also establishing internal AI centers of excellence, hiring data scientists, bioinformaticians, and computational chemists to integrate AI capabilities across departments. Cloud-based platforms and high-performance computing are being adopted to handle the massive volume of data generated from genomics, clinical studies, and digital health applications. AI-driven platforms are being used for portfolio prioritization, helping decision-makers assess which assets to advance or shelve based on predictive analytics. On the manufacturing side, AI supports process optimization, quality control, and predictive maintenance, ensuring consistent product quality and reducing operational costs. In sales and marketing, AI tools analyze market trends, prescription patterns, and customer feedback to develop personalized engagement strategies for healthcare providers and patients. Additionally, AI is playing a growing role in digital therapeutics and companion diagnostics, enabling the development of integrated treatment solutions that combine traditional drugs with software-driven monitoring and behavioral interventions. This shift toward AI-centric business models is not limited to large enterprises. Emerging biotech firms are using AI from day one to differentiate themselves, build leaner operations, and attract investment. As AI matures, it is becoming a strategic enabler that cuts across every phase of the pharmaceutical value chain, fostering a culture of innovation, speed, and precision.

What Is Driving the Sustained Global Growth of AI in the Pharma and Biotech Market?

The growth in the artificial intelligence in pharma and biotech market is driven by a combination of rising healthcare demands, expanding datasets, technological innovation, and a favorable regulatory and investment environment. The global burden of chronic and complex diseases such as cancer, Alzheimer’s, and rare genetic disorders is creating an urgent need for faster and more effective therapeutic solutions. AI helps meet this need by accelerating drug discovery and improving treatment precision. The widespread adoption of electronic health records, genomic sequencing, and wearable health devices has created a vast and growing pool of structured and unstructured data that fuels AI models. Technological advancements in natural language processing, machine learning, and neural networks have made it possible to analyze this data in ways that were previously unimaginable, unlocking insights that guide drug development, clinical decision-making, and market access strategies. Government initiatives and public-private partnerships aimed at fostering AI innovation in life sciences are also supporting growth, providing funding and policy support for research and deployment. Venture capital investment in AI-focused biotech startups continues to surge, reflecting strong confidence in the market potential of AI-driven drug development. The emergence of precision medicine and the push for patient-centric healthcare are further reinforcing the demand for AI tools that enable personalized treatment strategies. Global pharmaceutical companies are also under pressure to reduce costs and improve R&D efficiency, making AI a compelling solution for sustaining innovation. As more success stories emerge, such as AI-discovered drug candidates entering clinical trials, the credibility and adoption of AI in the life sciences continue to grow. These factors are collectively fueling a robust and sustained expansion of the AI market within the pharma and biotech sectors, signaling a new era of data-driven, technology-enabled healthcare innovation.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Pharma and Biotech market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application, Other Applications); End-User (Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Artificial Intelligence (AI) in Pharma and Biotech - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Costs and Long Development Cycles Spur Demand for AI-Driven Drug Discovery and Optimization Platforms
    • Here's How Generative AI Strengthens the Business Case for De Novo Molecule Design and Target Prediction
    • Integration of AI with Omics and Real-World Data Throws the Spotlight on Precision Medicine and Biomarker Discovery
    • Here's the Story: Natural Language Processing Enables Deep Mining of Scientific Literature and Biomedical Databases
    • AI-Powered Predictive Modeling Enhances Compound Screening, Toxicity Assessment, and Lead Candidate Prioritization
    • Digital Twins and Simulation Technologies Expand the Addressable Market for In Silico Testing and Virtual Clinical Trials
    • AI in Bioprocess Optimization and Manufacturing Improves Yield, Scalability, and Quality Control in Biotech Operations
    • Growing Focus on Rare Diseases and Orphan Drug Development Supports Use of AI to Identify Small, High-Impact Patient Populations
    • Here's the Story: Regulatory Acceptance of AI in Drug Development Workflows Drives Frameworks for Validation and Compliance
    • Integration of AI in Pharmacovigilance Enhances Post-Marketing Surveillance and Signal Detection Capabilities
    • Expansion of AI-Powered Platforms in Vaccine Development Demonstrates Potential in Rapid Response to Emerging Pathogens
    • Here's How Cloud Infrastructure and Data Interoperability Accelerate the Scalability of AI Tools Across the Drug Development Lifecycle
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence (AI) in Pharma and Biotech Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Clinical Trials & Optimization Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Clinical Trials & Optimization Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Predictive Maintenance & Quality Control Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Predictive Maintenance & Quality Control Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Target Identification Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Drug Target Identification Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Disease Diagnosis & Prognosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Disease Diagnosis & Prognosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academic & Contract Research Organizations End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Academic & Contract Research Organizations End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030

IV. COMPETITION